Symbol Lookup

Thursday May 28, 2015 5:46 AM ET. Data delayed 15 minutes.
9.72
0.00 (0.00%)
Bid/Lots
2.22/22
Ask/Lots
9.72/0
Open/Prev Close
0.00/9.72
Day Range
-----
52-Week Range
7.53-17.77
Vol/Avg Daily Vol
0.0/131.1K

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Retail Layoffs Highlight Opportunity in the Cannabis Space
10:48AM ET on Tuesday May 19, 2015 by Accesswire
Companies Mentioned: CARA

NEW YORK, NY / ACCESSWIRE / May 19, 2015 / On May 14, 2015, Shawn Phillips, owner of nine cannabis stores in Colorado, announced he had laid off 65 of his employees, accounting for approximately 45% of the company's total workforce. The stores are all part of a wider brand network called Strainwise, which currently operates 13 stores in Colorado, and sells marijuana both to recreational and medicinal users.

NEW YORK, NY / ACCESSWIRE / May 19, 2015 / On May 14, 2015, Shawn Phillips, owner of nine cannabis stores in Colorado, announced he had laid off 65 of his employees, accounting for approximately 45% of the company's total workforce. The stores ...

May 13, 2015

Cara Therapeutics Climbs 3% as Q1 Net Loss Beats Views; Provides Update on Pain Treatment I.V. CR845
11:10AM ET on Wednesday May 13, 2015 by Midnight Trader
Companies Mentioned: CARA
11:10 AM EDT, 05/13/2015 (MT Newswires) -- Shares of Cara Therapeutics Inc. (CARA) gained Wednesday morning after the Connecticut-based biotechnology firm reported mixed Q1 results late Tuesday, with a smaller-than-expected net loss on improved reve...
11:10 AM EDT, 05/13/2015 (MT Newswires) -- Shares of Cara Therapeutics Inc. (CARA) gained Wednesday morning after the Connecticut-based biotechnology firm reported mixed Q1 results late Tuesday, with a smaller-than-expected net loss on improved r...

May 12, 2015

Cara Therapeutics Reports First Quarter 2015 Financial Results
4:01PM ET on Tuesday May 12, 2015 by GlobeNewswire
Companies Mentioned: CARA

- End-of-Phase 2 Meeting With FDA Informs Phase 3 Clinical Development Program for Novel Kappa Opioid I.V. CR845 -

- Conference Call Today at 4:30 p.m. ET -

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the first quarter ended March 31, 2015 and provided an update on its Phase 3 Program for I.V. CR845.

- End-of-Phase 2 Meeting With FDA Informs Phase 3 Clinical Development Program for Novel Kappa Opioid I.V. CR845 -

- Conference Call Today at 4:30 p.m. ET -

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on...

Cara Therapeutics Reports First Quarter 2015 Financial Results
4:01PM ET on Tuesday May 12, 2015 by GlobeNewswire
Companies Mentioned: CARA

- End-of-Phase 2 Meeting With FDA Informs Phase 3 Clinical Development Program for Novel Kappa Opioid I.V. CR845 -

- Conference Call Today at 4:30 p.m. ET -

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the first quarter ended March 31, 2015 and provided an update on its Phase 3 Program for I.V. CR845.

- End-of-Phase 2 Meeting With FDA Informs Phase 3 Clinical Development Program for Novel Kappa Opioid I.V. CR845 -

- Conference Call Today at 4:30 p.m. ET -

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on...

May 6, 2015

Cara Therapeutics to Present at American Pain Society 34th Annual Scientific Meeting
8:00AM ET on Wednesday May 06, 2015 by GlobeNewswire
Companies Mentioned: CARA

-- Pain experts to discuss kappa opioid receptor agonists and latest developments in pain management

-- Company to present positive data from Phase 2, human abuse liability studies of I.V. CR845 during poster sessions

-- Pain experts to discuss kappa opioid receptor agonists and latest developments in pain management

-- Company to present positive data from Phase 2, human abuse liability studies of I.V. CR845 during poster sessions

← Newer12Older →

Peers Headlines

Yesterday

NeuroDerm Shares Fall 3% After Co Warns Doesn't Have Enough Cash to Complete R&D of Product Candidates
15 hours ago by Midnight Trader
Companies Mentioned: NDRM
02:13 PM EDT, 05/27/2015 (MT Newswires) -- NeuroDerm (NDRM) shares were lower nearly 3% on Wednesday after the pharmaceutical company developing central nervous system products said it currently doesn't have enough cash to complete the research a...
PlasmaTech Biopharmaceuticals to Present at the 2015 Marcum MicroCap Conference
21 hours ago by Marketwire
Companies Mentioned: PTBI

PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announces today that they will be present...

PlasmaTech Biopharmaceuticals to Present at the 2015 Marcum MicroCap Conference
21 hours ago by Marketwire Canada
Companies Mentioned: PTBI

PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announces today that they will be present...

May 26, 2015

REMINDER: PlasmaTech Biopharmaceuticals First Quarter 2015 Conference Call Tomorrow
1:16PM ET on Tuesday May 26, 2015 by Marketwire
Companies Mentioned: PTBI

PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, will provide a business update for invest...

REMINDER: PlasmaTech Biopharmaceuticals First Quarter 2015 Conference Call Tomorrow
1:15PM ET on Tuesday May 26, 2015 by Marketwire Canada
Companies Mentioned: PTBI

PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, will provide a business update for invest...

CytRx to Present at the Jefferies 2015 Global Healthcare Conference
9:00AM ET on Tuesday May 26, 2015 by PR Newswire
Companies Mentioned: CYTR

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer, and David Haen, Vice President of Business Developm...

May 21, 2015

CytRx Shares Climb on Encouraging Update From Phase 2 Trial of Aldoxorubicin in Deadly Form of Brain Cancer
9:40AM ET on Thursday May 21, 2015 by Midnight Trader
Companies Mentioned: CYTR
09:40 AM EDT, 05/21/2015 (MT Newswires) -- CytRx (CYTR) shares rose Thursday after the biopharmaceutical company specializing in oncology released encouraging updated results from its ongoing Phase 2 clinical trial with aldoxorubicin for the trea...

May 20, 2015

Sector Update: Health Care Stocks Trading Higher Pre-Bell
8:39AM ET on Wednesday May 20, 2015 by Midnight Trader
Companies Mentioned: STJ, PTBI, ETRM
08:39 AM EDT, 05/20/2015 (MT Newswires) -- Top Health-care stocks: JNJ: +0.5% PFE: +0.2% ABT: +0.4% MRK: flat AMGN: flat Health-care shares were mainly higher in pre-market trade Wednesday. In health-care stocks news, PlasmaTech Biopharmace...
Sector Update: Health Care
8:36AM ET on Wednesday May 20, 2015 by Midnight Trader
Companies Mentioned: PTBI, ETRM
08:36 AM EDT, 05/20/2015 (MT Newswires) -- Health-care shares were mainly higher in pre-market trade Wednesday. PlasmaTech Biopharmaceuticals (PTBI) shares were 10.1% higher in recent pre-market trade after saying the U.S. Food and Drug Administr...
PlasmaTech Biopharmaceuticals Gets FDA Orphan Drug Status For Two Product Candidates
8:17AM ET on Wednesday May 20, 2015 by Midnight Trader
Companies Mentioned: PTBI
08:17 AM EDT, 05/20/2015 (MT Newswires) -- PlasmaTech Biopharmaceuticals (PTBI) shares were higher nearly 9% in recent pre-market trade after saying the U.S. Food and Drug Administration has granted both orphan drug designation and rare pediatric...
← Newer123456Older →